| ŠPINAR, Jindřich, Jiří VÍTOVEC, Miroslav SOUČEK, Lenka ŠPINAROVÁ, Růžena LÁBROVÁ, Martina ŠIŠÁKOVÁ, Jiří JARKOVSKÝ, Jiří ŠPÁC a Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. Experimental and Clinical Cardiology. Ontario: Pulsus Group, 2014, roč. 20, č. 1, s. 662-673. ISSN 1205-6626. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1194852,
author = {Špinar, Jindřich and Vítovec, Jiří and Souček, Miroslav and Špinarová, Lenka and Lábrová, Růžena and Šišáková, Martina and Jarkovský, Jiří and Špác, Jiří and Ondrejková, Alena},
article_location = {Ontario},
article_number = {1},
keywords = {Atrial fibrillation; Bleeding; Dabigatran; Risk; Warfarin},
language = {eng},
issn = {1205-6626},
journal = {Experimental and Clinical Cardiology},
title = {The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation},
volume = {20},
year = {2014}
}
TY - JOUR
ID - 1194852
AU - Špinar, Jindřich - Vítovec, Jiří - Souček, Miroslav - Špinarová, Lenka - Lábrová, Růžena - Šišáková, Martina - Jarkovský, Jiří - Špác, Jiří - Ondrejková, Alena
PY - 2014
TI - The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation
JF - Experimental and Clinical Cardiology
VL - 20
IS - 1
SP - 662-673
EP - 662-673
PB - Pulsus Group
SN - 12056626
KW - Atrial fibrillation
KW - Bleeding
KW - Dabigatran
KW - Risk
KW - Warfarin
N2 - Aim: The FIRST registry aimed to compare patients with atrial fibrillation treated with dabigatran or warfarin. Methods: The study was performed in 10 centres in the Czech Republic. Results: Upon enrolment, 33.2% and 35.6% of patients respectively showed sinus rhythm. The last dose of warfarin before changing to dabigatran was higher than the maintenance dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients did not differ in the CHA2DS2-VASc score. The principal difference was in the HAS BLED score: 55.3% of patients treated with dabigatran demonstrated a score of three or more while only 33.5% of those treated with warfarin did (p < 0.001). In 14.7% of patients treated with dabigatran, serious bleeding was observed during the previous treatment with warfarin. In patients treated with warfarin serious bleeding occurred in 2.0%. The most frequent reason (56.6%) for changing over to dabigatran was the impossibility to maintain INR within the therapeutic range. Conclusion: Patients are transferred from warfarin to dabigatran in particular due to the impossibility to maintain INR within the therapeutic range, and these are more frequently patients with a higher bleeding risk.
ER -
ŠPINAR, Jindřich, Jiří VÍTOVEC, Miroslav SOUČEK, Lenka ŠPINAROVÁ, Růžena LÁBROVÁ, Martina ŠIŠÁKOVÁ, Jiří JARKOVSKÝ, Jiří ŠPÁC a Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. \textit{Experimental and Clinical Cardiology}. Ontario: Pulsus Group, 2014, roč.~20, č.~1, s.~662-673. ISSN~1205-6626.
|
